Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Chỉ hiển thị Multimedia

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC
12 Sep 2025
bởiAudrey Abella
Findings from the TALENTACE trial presented at ESMO GI 2025 support the combination of atezolizumab and bevacizumab after transarterial chemoembolization (TACE) for the treatment of individuals with systemically untreated, intermediate-to-high tumour burden, unresectable hepatocellular carcinoma (HCC).
TALENTACE supports atezolizumab + bevacizumab after TACE for HCC
12 Sep 2025
Common blood test predicts which AD patients will have rapid cognitive decline
11 Sep 2025
bởiElvira Manzano
Insulin resistance, detected through the routine triglyceride-glucose (TyG) index, identifies individuals with early Alzheimer’s disease (AD) who are four times more likely to experience rapid cognitive decline, findings from a new study presented at EAN 2025 suggest.







